logo

Durect Corp. (DRRX)



Trade DRRX now with
  Date
  Headline
6/20/2019 8:09:56 AM DURECT Announces $15 Mln Registered Direct Offering
6/18/2019 8:08:54 AM DURECT Completes Dosing 90 Mg Cohort Of Severe AH Patients In Ongoing DUR-928 Phase 2a Clinical Trial
3/27/2019 8:03:21 AM DURECT Announces Patient Enrollment In Phase 1b Clinical Trial Of Oral DUR-928 In Patients With NASH
3/21/2019 8:03:44 AM DURECT Begins Patient Dosing In Phase 2a Proof-of-concept Trial With Topical DUR-928
2/27/2019 7:07:46 AM DURECT Corp. Says Plans To Submit To FDA Full Response To POSIMIR Complete Response Letter
12/17/2018 8:24:29 AM DURECT: Felix Theeuwes To Retire As Chairman Of Board And Distinguished Scientist
10/1/2018 8:09:36 AM DURECT Corporation Appoints Michael Arenberg As CFO
8/6/2018 9:22:49 AM DURECT's Licensee Pain Therapeutics Gets Complete Response Letter From FDA For REMOXY ER Extended-Release Capsules CII
7/30/2018 8:08:46 AM DURECT Reports FDA Approval Of Indivior's PERSERIS Extended-Release Injectable Suspension For Schizophrenia In Adults
6/26/2018 8:34:34 PM DURECT Says FDA Advisory Committee Votes 14 To 3 Against Approval Of REMOXY
5/9/2018 8:04:38 AM DURECT Enters Amendment To Licensing Agreement With Sandoz Related To POSIMIR
4/25/2018 8:03:53 AM DURECT Announces Patient Dosing In Phase 2a Trial Of DUR-928 In Alcoholic Hepatitis
3/20/2018 8:09:37 AM DURECT Announces FDA Advisory Committee Meeting For REMOXY ER; Tentative Date For The Meeting Is June 26
2/26/2018 8:15:06 AM DURECT Begins Patient Dosing In Phase 2a Clinical Trial Of DUR-928 In Patients With Primary Sclerosing Cholangitis